Clinical Trials Browser

INDUSTRY × Ramucirumab × Gastrointestinal × Clear all

NCT04704934 2026-05-27

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Phase 3 Active not recruiting

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT06445972 2026-05-12

MK-3475-06D

Phase 1/2 Recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT03798626 2026-04-01

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Phase 1 Completed

GastrointestinalGenitourinary

Carcinoma, Renal Cell, Colorectal Neoplasms

NCT03281369 2025-12-15

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Phase 1/2 Completed

Gastrointestinal

Esophageal Neoplasms

NCT05980416 2025-11-14

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Phase 1 Terminated

88 enrolled 18 charts

Gastrointestinal

Adenocarcinoma, Digestive System Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Neoplasms by Site, Stomach Neoplasms

NCT05071053 2025-08-22

CARMEN-GC01

Phase 2 Terminated

35 enrolled 14 charts

Gastrointestinal

Adenocarcinoma Gastric

NCT05002127 2025-08-07

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

Phase 2/3 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT02711553 2025-08-03

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

Phase 2 Active not recruiting

309 enrolled 22 charts

Gastrointestinal

Biliary Tract Neoplasms, Neoplasm Metastasis

NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Phase 1 Active not recruiting

DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT06038578 2025-08-03

A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT05311176 2025-05-11

nextHERIZON

Phase 2 Terminated

7 enrolled 8 charts

Gastrointestinal

Stomach Neoplasms

NCT04499924 2025-01-22

MOUNTAINEER-02

Phase 2/3 Completed

17 enrolled 23 charts

Gastrointestinal

Adenocarcinoma Of Esophagus

NCT02065765 2025-01-09

International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer

Approved for marketing

Gastrointestinal

Stomach Neoplasms

NCT02307812 2025-01-09

Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France

Approved for marketing

Gastrointestinal

Stomach Neoplasms

NCT02791334 2024-09-27

PACT

Phase 1 Completed

BreastDermatologicGastrointestinal

Breast Neoplasms, Melanoma, Pancreatic Neoplasms

NCT04999761 2024-09-25

AB122 Platform Study

Phase 1 Recruiting

GastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Sarcoma, Alveolar Soft Part

NCT02443324 2024-07-31

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Phase 1 Completed

175 enrolled 23 charts

GastrointestinalGenitourinaryThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT06123494 2024-01-16

SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen

Phase 3 Recruiting

Gastrointestinal

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

NCT05800418 2023-04-05

Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male Volunteers

Phase 1 Completed

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Stomach Neoplasms

NCT02435433 2023-01-20

REACH-2

Phase 3 Completed

399 enrolled 22 charts 1 FDA

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05190445 2022-09-08

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

Phase 2 Active not recruiting

Gastrointestinal

HER2-positive Gastric Cancer

NCT02898077 2022-06-14

A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer

Phase 3 Completed

440 enrolled 19 charts

Gastrointestinal

Gastroesophageal Junction Adenocarcinoma

NCT02970539 2022-02-16

Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers

Phase 1 Unknown

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT02314117 2021-08-26

RAINFALL

Phase 3 Completed

645 enrolled 22 charts

Gastrointestinal

Metastatic Gastric Adenocarcinoma

NCT02572687 2021-01-20

A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

Phase 1 Completed

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Neoplasm Metastasis, Stomach Neoplasms

NCT01246986 2021-01-12

A Study of LY2157299 in Participants With Hepatocellular Carcinoma

Phase 2 Completed

204 enrolled 27 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT02082210 2020-12-19

A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer

Phase 1/2 Completed

97 enrolled 20 charts

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Liver Neoplasms

NCT02443883 2020-06-29

A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer

Phase 2 Completed

164 enrolled 13 charts

Gastrointestinal

Stomach Neoplasms

NCT02514551 2020-06-17

A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer

Phase 2 Completed

245 enrolled 17 charts

Gastrointestinal

Stomach Neoplasms

NCT03704077 2020-05-19

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Stomach Neoplasms

NCT01983878 2019-09-30

A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer

Phase 2 Completed

36 enrolled 21 charts

Gastrointestinal

Stomach Neoplasms

NCT00917384 2019-09-25

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

Phase 3 Completed

355 enrolled 16 charts

Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Stomach Neoplasms

NCT01183780 2019-09-25

A Study in Second Line Metastatic Colorectal Cancer

Phase 3 Completed

1,072 enrolled 17 charts

Gastrointestinal

Colorectal Neoplasms

NCT01170663 2019-09-18

RAINBOW

Phase 3 Completed

665 enrolled 24 charts

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT01111604 2019-08-06

A Study of Ramucirumab or Icrucumab in Colorectal Cancer

Phase 2 Completed

158 enrolled 17 charts

Gastrointestinal

Adenocarcinoma, Colonic Neoplasms, Rectal Neoplasms

NCT02745769 2019-03-05

A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents

Phase 1 Completed

GastrointestinalLymphoid

Colorectal Neoplasms, Lymphoma, Mantle-Cell

NCT02069041 2018-11-21

A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer

Phase 1 Completed

8 enrolled 16 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT02359058 2018-01-24

A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer

Phase 1 Completed

18 enrolled 13 charts

Gastrointestinal

Stomach Neoplasms

NCT01140347 2015-12-28

REACH

Phase 3 Completed

565 enrolled 22 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT00627042 2014-10-08

Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy

Phase 2 Completed

42 enrolled 19 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms

NCT01246960 2014-10-08

A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer

Phase 2 Completed

168 enrolled 16 charts

Gastrointestinal

Esophageal Neoplasms, Neoplasms, Stomach Neoplasms

NCT01286818 2014-10-06

A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)

Phase 1 Completed

6 enrolled 12 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00862784 2014-06-17

A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer

Phase 2 Completed

48 enrolled 15 charts

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms